NasdaqGM:FLGTHealthcare
Fulgent Genetics (FLGT) Trailing US$60 Million Loss Tests Bullish Margin Narratives
Fulgent Genetics Q1 2026 earnings snapshot
Fulgent Genetics (FLGT) has entered Q1 2026 with trailing 12 month revenue of US$322.7 million and a basic EPS loss of US$1.97. This sets up another quarter where the top line shows scale, while profitability remains under pressure. Over recent quarters, revenue has moved from US$76.2 million in Q4 2024 to US$83.3 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.19 to a loss of US$0.76. This highlights that growth in...